Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 3/19/26 | Rhythm (RYTM) | Imcivree for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/19/26 | Pfizer (PFE) | Talzenna for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/17/26 | Ascendis Pharma (ASND) | Skytrofa for Turner Syndrome | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/17/26 | Greenwich LifeSciences (GLSI) | GLSI-100 for HER2+ Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/16/26 | Structure (GPCR) | GSBR-1290 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |